Table 1.

Chi-square analyses for association between clinicopathological features and positive rates of CagA or PD-L1 protein expression or the level of exosomal PD-L1 protein in 87 Hp-infected GC

Clusters	Patients	CagA (+)		PD-L1 (+)		Exo PD-L1
	Count (%)	Count (%)	p	Count (%)	p	Mean ± SD	p
Sex			0.850		0.720		0.709
Male	57 (65.5%)	41 (71.9%)		30 (52.6%)		1.00 ± 0.51
Female	30 (34.5%)	21 (70.0%)		17 (56.7%)		1.05 ± 0.58
Age			0.660		0.523		0.450
≤60	49 (56.3%)	34 (69.4%)		25 (51.0%)		1.05 ± 0.55
>60	38 (43.7%)	28 (73.7%)		22 (57.9%)		0.97 ± 0.46
Lauren type			0.025		0.489		0.375
Intestinala	51 (58.6%)	41 (80.4%)		26 (51.0%)		1.06 ± 0.54
Diffuse	36 (41.4%)	21 (58.3%)		21 (58.3%)		0.96 ± 0.46
Differentiation type			0.360		0.022		0.023
Undifferentiated and poor	42 (48.3%)	28 (66.7%)		28 (66.7%)		1.15 ± 0.54
Moderate and well	45 (51.7%)	34 (75.6%)		19 (42.2%)		0.90 ± 0.46
Serum CEA			0.469		0.210		0.226
<5 ng/mL	54 (62.1%)	37 (68.5%)		32 (59.3%)		1.07 ± 0.54
≥5 ng/mL	33 (37.9%)	25 (75.8%)		15 (45.5%)		0.93 ± 0.45
Tumor diameter			0.711		0.097		0.078
≤5 cm	46 (52.9%)	32 (69.6%)		21 (45.7%)		0.93 ± 0.53
>5 cm	41 (47.1%)	30 (73.2%)		26 (63.4%)		1.12 ± 0.48
T stage			0.042		0.026		0.011
T1-T2	19 (21.8%)	10 (52.6%)		6 (31.6%)		0.76 ± 0.56
T3-T4	68 (78.2%)	52 (76.5%)		41 (60.3%)		1.09 ± 0.48
N stage			0.012		0.009		0.003
Negative	25 (28.7%)	13 (52.0%)		8 (32.0%)		0.76 ± 0.55
Positive	62 (71.3%)	49 (79.0%)		39 (62.9%)		1.12 ± 0.46
TNM stage			0.002		0.005		0.001
I-II	34 (39.1%)	18 (52.9%)		12 (35.3%)		0.79 ± 0.49
III-IV	53 (60.1%)	44 (83.0%)		35 (66.0%)		1.16 ± 0.48

^aIntestinal type including intestinal, mixed, and other types.